论文部分内容阅读
目的:观察非小细胞肺癌组织与癌旁组织中Bcl-xL的基因转录和蛋白表达水平,探讨Bcl-xL在非小细胞肺癌发生发展中的可能作用,为非小细胞肺癌的诊断和治疗提供参考。方法:反转录PCR和免疫印迹的方法分别检测60例临床确诊的非小细胞肺癌组织与癌旁组织中Bcl-xL基因表达和Bcl-xL蛋白的水平,并与肺良性病变组织比较。结果:非小细胞肺癌组织的Bcl-xL mRNA水平明显高于癌旁组织和肺良性病变组织(P<0.01),mR-NA水平与临床分期呈正相关,与其他临床病理相关因素(性别、年龄、肿瘤大小、发生部位、组织学类型、分化程度)无明显相关,而癌旁组织和肺良性病变组织Bcl-xL mRNA水平之间没有差别(P>0.05)。蛋白表达检测结果与mR-NA水平高度一致。结论:非小细胞肺癌组织中Bcl-xL基因和蛋白表达水平明显升高,可能促进了肿瘤的发生发展,可以考虑作为非小细胞肺癌临床分期和评价临床预后的参考指标。
OBJECTIVE: To observe the gene transcription and protein expression of Bcl-xL in non-small cell lung cancer tissues and pericarcinomatous tissues and to explore the possible role of Bcl-xL in the development of non-small cell lung cancer (NSCLC) and to provide a basis for the diagnosis and treatment of non-small cell lung cancer reference. Methods: The expressions of Bcl-xL gene and Bcl-xL protein in 60 clinically diagnosed non-small cell lung cancer tissues and pericarcinomatous tissues were detected by RT-PCR and Western blot, respectively, and compared with benign lung tissues. Results: The level of Bcl-xL mRNA in non-small cell lung cancer tissues was significantly higher than that in paracancerous tissues and benign lung tissues (P <0.01). The level of mR-NA was positively correlated with clinical stage and with other clinicopathological factors , Tumor size, site of occurrence, histological type and degree of differentiation). There was no difference between Bcl-xL mRNA levels in adjacent non-cancerous tissues and benign lung tissues (P> 0.05). The result of protein expression was highly consistent with the level of mR-NA. CONCLUSIONS: The expression of Bcl-xL gene and protein in non-small cell lung cancer is significantly increased, which may promote the development of tumor. It may be taken as a reference index for clinical stage and clinical prognosis of non-small cell lung cancer.